A federal court ruling has halted the work of a key vaccine advisory panel, leaving U.S. health officials without clear guidance on COVID-19 and flu vaccinations as the next respiratory disease season approaches.

The decision by U.S. District Judge Brian Murphy effectively froze the activities of the Advisory Committee on Immunization Practices, which provides recommendations to the Centers for Disease Control and Prevention on how vaccines should be used.

Murphy ruled that most members of the panel appointed last year under Robert F. Kennedy Jr. were unqualified, ordering that their votes be put on hold. The ruling reinstates the prior childhood immunization schedule and leaves the CDC without a functioning advisory body to evaluate new vaccines or updated uses of existing ones.

Without formal recommendations from the panel, vaccines approved by the Food and Drug Administration may still be available but could face uncertainty around insurance coverage and inclusion in federal programs. Health experts say insurers often rely on these recommendations when determining reimbursement.

The disruption comes at a critical time, as updated COVID-19 and seasonal flu vaccines are typically reviewed and recommended ahead of the fall. While flu shots have longstanding universal guidance that may carry forward, COVID-19 vaccines, updated annually for evolving variants, could face ambiguity without a new recommendation.

The situation also affects other immunization decisions, including guidance for respiratory syncytial virus (RSV) vaccines and ongoing reviews of vaccine schedules, such as the number of doses needed for HPV protection.

Several newly approved or pending vaccines remain in limbo awaiting federal guidance, including RSV vaccines from major pharmaceutical companies and experimental products still under review. Without a functioning advisory panel, these vaccines could reach the market without clear federal direction on who should receive them.

The Department of Health and Human Services has not outlined a timeline for resolving the issue, leaving open questions about whether the panel will be reconstituted, the ruling appealed, or alternative mechanisms used to issue recommendations.

With the fall vaccination season approaching, the lack of clarity could complicate planning for providers, insurers, and patients, particularly if updated COVID-19 guidance is delayed or absent.